Dosing will begin later this month with ImmuPharma PLC (AIM:IMM, OTC:IMMPF)’s Lupuzor treatment to assess how a new formulation of the lupus treatment interacts with the body.
After approval from the UK’s Medical and Health Products Regulatory Agency, the pharmacokinetic (PK) study in 24 healthy male volunteers will get underway on February 15.
Results should be available by the end of the current quarter.
The new synthesis of Lupuzor, also known as P140, will afford “greater IP protection and lower cost of goods”, ImmuPharma said.
The company has been working on preparations for the drug evaluation with its US partner Avion Pharmaceuticals and contract research group Simbec-Orion.
The PK study is part of the new, optimised international phase III trial of Lupuzor in patients with lupus, a condition where the immune system attacks the body’s own tissue and organs.